Remove Licensing Remove Targeted Protein Degradation Remove Therapies
article thumbnail

Six collaborations driving drug discovery innovation

Drug Discovery World

The collaboration leverages Evotec’s R&D platform to advance drug discovery for two drug targets that address major unmet medical needs of patients with Crohn’s disease and ulcerative colitis. of Perspective’s shares for up to $33 million. of Perspective’s shares for up to $33 million.

article thumbnail

Industry collaborations advancing drug discovery

Drug Discovery World

It will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration, with the aim to accelerate the discovery of new therapies for people living with Huntington’s disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 189
article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer. Arvinas and Pfizer are seeking to develop ARV-471 as the potential endocrine therapy of choice for patients and their physicians.

article thumbnail

Patent Highlights: Allosteric AR Modulators, Glycogen Synthase Inhibitors, and More

Drug Hunter

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.